Lack of IPOs Not a Bad Thing for Life Sciences
There's no denying the IPO window is pretty narrow for venture-backed companies, especially for those in life sciences. Of the five VC-backed IPOs last quarter (which, by the way, was the most VC-backed offerings since Q1 2008) none were in the life sciences field. But that's not a bad thing, says Mark Brooks, managing director of Scale Venture Partners. The Foster City, Calif.-based firm last year had one of the better IPOs in recent memory when portfolio company IPC Inc., a provider of information management systems to hospitals and physician groups, went public at $16 a share. IPC (Nasdaq: IPCM) closed today at $26.45 a share.
22 July 2009•2 mins read
